

 #CARDIOTOX [CARDIOTOX.ES](https://www.cardiotox.es)

CARDIOTOX 26

12-13 NOVEMBER

MADRID



VENUE

Meeting Place Castellana 81, Madrid

CARDIOTOX 26

12-13 NOVEMBER
MADRID

VENUE Meeting Place Castellana 81, Madrid

Thursday, 12th November

08:30 – 09:00 **Welcome and registration**

09:00 – 09:10 **Inauguration**

09:10 – 09:50 **CARDIO-ONCOLOGY IN 2026**

Translating cardio-oncology advances into clinical care

09:10 – 09:25 Cardio-oncology 2026: key advances for the clinic

09:25 – 09:40 Proton therapy: is the heart still at risk?

09:40 – 09:50 Discussion

09:50 – 10:45 **FROM BENCH TO BEDSIDE**

Immune cancer therapies and the mechanisms underlying cardiac immune-related adverse events

09:50 – 10:00 Mechanisms of ICI-related myotoxicity

10:00 – 10:10 ICI myotoxicity: from mechanisms to targeted treatment

10:10 – 10:20 Translational biomarkers in immune-related cardiotoxicity: from inflammatory cells to risk stratification

10:20 – 10:30 T cell-based cancer therapies and associated cardiac irAEs

10:30 – 10:45 Discussion

10:45 – 11:15 **Coffee break**

11:15 – 12:00 **MEET THE EXPERTS**

Lung cancer therapies: cardiovascular risk, rechallenge and practical surveillance.

11:15 – 11:25 ICI rechallenge after myocarditis: time for reassessment?

11:25 – 11:35 EGFR-targeted therapies: cardiovascular toxicity and monitoring

11:35 – 11:45 ALK inhibitors: practical surveillance and metabolic management

11:45 – 12:00 Discussion

12:00 – 12:40

IN FOCUS

Tyrosine kinase inhibitors in CML: balancing vascular risk and treatment efficacy

Panel discussion

12:40 – 13:40

CARDIAC IMAGING IN CARDIO-ONCOLOGY

Imaging-led decisions in cardio-oncology: when to act? when to wait?

12:40 – 12:50

GLS drop: treat or observe?

12:50 – 13:00

CMR: When does it alter therapy?

13:00 – 13:10

CMR in suspected ICI-myocarditis: diagnostic thresholds and pitfalls

13:10 – 13:20

Asymptomatic ASCVD in cancer survivorship: what next?

13:20 – 13:40

Discussion

13:40 – 15:30

Lunch break: Tutorials / Satellite Symposium

15:30 – 16:30

FROM BENCH TO BEDSIDE

The vicious cycle of cancer therapy-induced cardiac injury: mechanisms and treatment windows

15:30 – 15:40

Anthracycline cardiotoxicity: molecular mechanisms that inform prevention

15:40 – 15:50

Exercise in CTRCD: mechanistic rationale and treatment windows

15:50 – 16:00

Neurohormonal inhibition in CTRCD: preclinical and clinical evidence

16:00 – 16:10

Reversible vs irreversible CTRCD: biological continuum or distinct entities?

16:10 – 16:30

Discussion

16:30 – 17:30

CLINICAL CASE FORUM

Acute cardio-oncology: are we ready for the 24-hour challenge?

16:30 – 16:45

ICI-myotoxicity: early signals and grey zones

16:45 – 17:00

Acute coronary syndrome during cancer treatment

17:00 – 17:15

Cardiovascular complications of CRS in CAR-T therapy

17:15 – 17:30

Acute pulmonary embolism in cancer: when to escalate

17:30 – 19:00

TUTORIALS / SATELLITE SYMPOSIUM

Friday, 13th November

08:30 – 09:15 SYMPOSIUM

- 08:30 – 08:40 Cardiovascular risk across cancer therapies and survivorship
- 08:30 – 08:40 Cardiovascular risk with immunotherapy-based combinations
- 08:40 – 08:50 Endocrine and targeted therapies in breast cancer: the unresolved long-term cardiovascular burden
- 08:50 – 09:00 Biomarkers for risk stratification and long-term surveillance
- 09:00 – 09:15 Discussion
-

09:15 – 10:00 IN FOCUS

- 09:15 – 09:25 Cardiac amyloidosis in the cardio-oncology clinic: recognition and targeted therapies
- 09:15 – 09:25 Clinical and imaging red flags
- 09:25 – 09:35 ATTR cardiac amyloidosis: recent therapeutic advances
- 09:35 – 09:45 AL cardiac amyloidosis: emerging treatment strategies and cardiac outcomes
- 09:45 – 10:00 Discussion
-

10:00 – 11:00 CLINICAL CASE FORUM

- 10:00 – 11:00 Vascular and valvular cardio-oncology: recognition, timing and management priorities
- 10:00 – 10:15 Fluoropyrimidine-associated chest pain: acute management and next steps
- 10:15 – 10:30 Severe aortic stenosis in active cancer: timing TAVI and competing clinical priorities
- 10:30 – 10:45 When anticoagulation leads to bleeding: what to do and when to act?
- 10:45 – 11:00 CV surveillance after HSCT: defining who is truly high-risk

11:00 – 11:30 Coffee break

11:30 – 12:30	FROM BENCH TO BEDSIDE Genetic and acquired determinants of cardiotoxicity: from predisposition to second hits
11:30 – 11:40	CHIP as a cardiovascular risk modifier: what matters in cardio-oncology?
11:40 – 11:50	CHIP in lymphoma: biological links and implications for cardiac injury
11:50 – 12:00	TTN truncating variants before anthracycline therapy: proceed, modify or protect?
12:00 – 12:10	Cardiomyopathy variants and cardiotoxicity: second hit or misdiagnosis
12:10 – 12:30	Discussion

12:30 – 13:15	MEET THE EXPERTS Anticipating and managing cardiovascular risk in patients with prostate and renal cancer
12:30 – 12:40	Cardiovascular adverse events with tyrosine-kinase inhibitors for renal cancer
12:40 – 12:50	Hormone therapy for prostate cancer and cardiovascular toxicity
12:50 – 13:00	Pre-treatment assessments in patients with prostate cancer
13:00 – 13:15	Discussion

13:15 – 14:00	IN FOCUS BTK inhibitors in CLL: new strategies, new cardiovascular questions
13:15 – 13:25	Real-world evidence: beyond clinical trials
13:25 – 13:35	Finite vs continuous treatment: cardiovascular risk after treatment discontinuation
13:35 – 13:45	Non-covalent BTK inhibitors: a new drug class with a favourable cardiovascular safety profile
13:45 – 14:00	Discussion

14:00 – 15:30 **Lunch break: Tutorials / Satellite Symposium**

CARDIOTOX 26

12-13 NOVEMBER
MADRID

VENUE Meeting Place Castellana 81, Madrid

15:30 – 16:30	CLINICAL CASE FORUM Prevention and permissive cardiotoxicity: are we doing too much or too little?
15:30 – 15:40	Obesity in cancer care: ignore or treat from day one?
15:40 – 15:50	Albuminuria during VEGF inhibition: marker or mandate to act
15:50 – 16:00	Permissive cardiotoxicity: LVEF-led or context-led decision-making?
16:00 – 16:10	Myocardial injury in acute leukaemia: a triple-hit of host, disease, and treatment
16:10 – 16:30	Discussion

16:30 – 17:30	SYMPOSIUM Building the roadmap for the next generation of cardio-oncology care
16:30 – 16:45	Translational research priorities in cardio-oncology
16:45 – 17:00	Cardio-oncology roadmap: from trials and real-world data to future guidelines
17:00 – 17:15	Discussion

17:15 – 17:30 **CLOSING REMARKS**

CARDIOTOX 26

12-13 NOVEMBER

MADRID



Secretaría técnica

 **tactics**

 Barcelona · Madrid

 93 451 17 24

 info@tacticsmd.net

 www.tacticsmd.net